Research programme: influenza virus vaccines - Vaxart

Drug Profile

Research programme: influenza virus vaccines - Vaxart

Alternative Names: H1N1 swine influenza vaccine - Vaxart; H3N2 seasonal influenza vaccine - Vaxart; H7N9 avian influenza vaccine - Vaxart; Oral quadrivalent seasonal influenza vaccine - Vaxart

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vaxart
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H3N2 subtype; Influenza A virus H7N9 subtype
  • Discontinued Influenza A virus H1N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype(Prevention) in USA (PO, Tablet)
  • 16 Jul 2016 No recent reports of development identified for research development in Influenza-A virus H3N2 subtype(Prevention) in USA (PO, Tablet)
  • 26 Jun 2013 Preclinical trials in Influenza-A virus H7N9 subtype in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top